Savers are quickly becoming one of the biggest casualties of the post-financial crisis world. The simple reason is that, as central banks keep interest rates at close to zero to revive their struggling economies, the yields on both cash deposits and bonds are so low that many are finding it almost impossible to generate enough income from their hard-earned savings.
The recent crisis in Europe has highlighted the shortcomings in the economic and political framework of the region. While in many respects the European integration project has been a great success, if it is to survive, it seems clear that further integration will be necessary to avoid a similar fallout in the future.
Not so long ago, Europe was a place to avoid for many investors. As fears of a euro break-up intensified, understandably many steered clear of the region. However, as signs of stability began to emerge last year, investors once again began to move back into European stocks.
During the depths of the crisis, Europe was largely un-investable. Even the remote prospect of the euro not surviving was more than enough to deter investors, but with conditions now starting to stabilise, investors are coming back in droves looking to pick up property and other cheap assets across the continent.
It is just over 90 years since the foundation of an independent Irish State and we are facing some important commemorations in the next few years: 1916 in just three years’ time and the centenary celebrations of the foundation of the State itself in 2022.
In the past year a number of very high profile Merger and Acquisition (‘M&A’) deals have been announced. This has led some to question whether we are on the cusp of another M&A boom similar to the late 1990s.
The global economy now appears to have expanded by just under 3% in 2013, a slightly slower rate than in 2012. However, momentum gathered pace in many regions as the year came to an end.
Sandra Rockett outlines how changes to the Pension Fund Limit may impact you.
The opportunity for branded goods increasingly lies in faster growing emerging markets. For more than a decade, nations like Brazil, Russia, India and China (“BRICs”) have grown at much faster rates than the West, which has created a burgeoning middle class of several hundred million people.
Investors are now fully aware of the ‘patent cliff’ that the Pharmaceutical and Biotech industries are currently going through. During the period 2011-2017, every single one of the current top 20 largest selling drugs in the world will begin to face generic competition. While this issue has been an overhang for the industry for some years, the ‘unknown’ is how the industry will adapt and evolve to overcome this and other issues it currently faces.